Eisai to add capacityIllustrative image – not actual.

Eisai Pharmatechnology and Manufacturing, a wholly owned subsidiary of Tokyo based Eisai Company, is planning to invest about Rs 100 crore in India to expand its manufacturing capacity and research capabilities at Visakhapatnam in Andhra Pradesh. The company has already invested $50 million (approx Rs 232.5 crore) in India.

The proposed capex is likely to be utilised to augment the manufacturing capacity of Active Pharmaceutical Ingredients (APIs) and product research at the Eisai Knowledge Centre, Visakhapatnam. The company plans to shift manufacturing of three more new products (in addition to the two which have already been shifted) to India.

The first batch of Aricep (for dementia patients) manufactured in India is likely to be rolled out from its plant by end-July 2010. This is to be followed by Parit (rabeprozal sodium), followed by two more drugs.

On the research front, the Eisai Knowledge Centre is working on five projects. Of these, three are process development projects and the remaining two are on development of new molecules in the therapeutic areas of cardiovascular and central nervous system.

← All latest storiesBack to top →